Outlook Therapeutics, Inc. - Common Stock (OTLK)

Last Price0.7564

Change-0.1324 (-14.90%)

NASDAQ· Last Trade: Aug 15th, 12:45 PM EDT

Detailed Quote

Previous Close	0.8888
Open	0.8438
Bid	0.7899
Ask	0.7989
Day's Range	0.7120 - 0.8438
52 Week Range	0.1611 - 3.390
Volume	104,623,251
Market Cap	40.76M
PE Ratio (TTM)	-0.2887
EPS (TTM)	-2.6
Dividend & Yield	N/A (N/A)
1 Month Average Volume	20,709,273

About Outlook Therapeutics, Inc. - Common Stock (OTLK)

Outlook Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative treatments for eye diseases. The company specializes in the research and advancement of therapies aimed at addressing significant unmet medical needs in ophthalmology. Through its proprietary drug pipeline, Outlook Therapeutics is committed to enhancing the quality of life for patients affected by various retinal conditions, striving to bring new possibilities and improved outcomes to vision care. Read More

News & Press Releases

Friday's session: most active stockschartmill.com

Via Chartmill · August 14, 2026

Oncobiologics Q3 Earnings Call Highlightsmarketbeat.com

Oncobiologics (NASDAQ:OTLK) said it is preparing for the U.S. commercial launch of LYTENAVA after the Food and Drug Administration approved the product as the only FDA-approved ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration, or wet AMD, in the United

Via MarketBeat · August 14, 2026

Transcript: Outlook Therapeutics Q3 2026 Earnings Conference Callbenzinga.com

Outlook Therapeutics (NASDAQ:OTLK) released third-quarter financial results and hosted an earnings call on Friday. Read the complete transcript below. This transcript is brought to you by Benzinga APIs. For real-time

Via Benzinga · August 14, 2026